---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-271117"
form_type: "8-K"
ticker: "ADPT"
cik: "0001478320"
company_name: "Adaptive Biotechnologies Corp"
filed_at: "2026-06-15T20:15:51+00:00"
generated_at: "2026-06-15T20:27:18.794052+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Adaptive Biotechnologies proposes $250M notes offering, plans MRD/Immune Medicine separation

## Summary
- Intends to issue $250M convertible senior notes due 2031 (plus $37.5M option) to qualified institutional buyers.
- Proceeds to repay OrbiMed Purchase Agreement (~$156.9M), repurchase up to $25M stock, and fund capped calls.
- Plans to separate MRD and Immune Medicine businesses; expects to identify preferred path by year-end 2026.
- MRD revenue grew to $212M in 2025 (from $103M in 2023), with $15M adjusted EBITDA.
- Immune Medicine has over 6M functional TCR-antigen pairs and data on 10,000+ patients; evaluating alternatives.

## SEC filing metadata
- accession: 0001193125-26-271117
- form_type: 8-K
- ticker: ADPT
- cik: 0001478320
- company_name: Adaptive Biotechnologies Corp
- filed_at: 2026-06-15T20:15:51+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1478320/000119312526271117/0001193125-26-271117-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1478320/000119312526271117/d65233d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-271117
- JSON: https://secwatch.observer/filing/0001193125-26-271117.json
- Plain text: https://secwatch.observer/filing/0001193125-26-271117.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.